← Library
CJC-1295 (no DAC / Mod GRF 1-29)
Research Use
Also known as Mod GRF 1-29, CJC-1295 no DAC
Function
Primary
Physiologic GH pulse amplification
Secondary
Anti-aging · Sleep quality
Mechanism
Short-acting GHRH analog (t½ ~30 min) — preserves pulsatile GH secretion; often combined with Ipamorelin for synergy.
Evidence
Pre-clinical / Observational
Research
Pre-clinical and observational only
Dosing
Range
100–300 mcg/dose
Frequency
2–3× daily or before sleep
Route
Subcutaneous
Cycling
8–12 weeks on / 4 weeks off.
Benefits
- ·Preserves natural GH pulsatility
- ·Improved sleep and recovery (anecdotal)
- ·Synergistic with GHRPs
Risks
- ·Water retention
- ·Headache
- ·IGF-1 elevation
- ·Theoretical oncogenicity
Contraindications
- ·Active malignancy
- ·Pregnancy
- ·Severe diabetic retinopathy
Regulatory
Not FDA-approved; compounded/research use
Functional Groups
Cited Works
- Teichman SL et al. Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91:799.source